Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)
Status:
Terminated
Trial end date:
2020-07-14
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, cross-over (placebo or elafibranor [GFT505])
placebo-controlled study, will evaluate the effect on hepatic lipid composition and safety of
elafibranor 120 mg quaque die (QD) versus placebo in an adult NAFL population after 6 weeks
of treatment with a 4-week wash-out period. This study will achieve mechanistic information
about the mode of action of Elafibranor on the (lipid) metabolism in the human fatty liver